Appili Therapeutics (APLIF)
(Delayed Data from OTC)
$0.03 USD
-0.01 (-16.67%)
Updated May 1, 2024 03:31 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Appili Therapeutics Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 | |
---|---|---|---|---|---|
Sales | NA | 0 | 1 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 6 | 21 | 12 | 5 |
Income After Depreciation & Amortization | 0 | -6 | -20 | -12 | -5 |
Non-Operating Income | NA | 0 | 0 | 1 | 1 |
Interest Expense | NA | 1 | 0 | 0 | 0 |
Pretax Income | NA | -7 | -20 | -11 | -4 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -7 | -20 | -11 | -4 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -7 | -20 | -11 | -4 |
Depreciation Footnote | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -6 | -20 | -12 | -5 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -6 | -20 | -12 | -5 |
Earnings Per Share Data | 3/31/24 | 3/31/23 | 3/31/22 | 3/31/21 | 3/31/20 |
---|---|---|---|---|---|
Average Shares | NA | 113.73 | 66.73 | 59.18 | 34.33 |
Diluted EPS Before Non-Recurring Items | NA | -0.06 | -0.30 | -0.18 | -0.12 |
Diluted Net EPS (GAAP) | NA | -0.06 | -0.30 | -0.18 | -0.12 |
Fiscal Year end for Appili Therapeutics Inc falls in the month of March .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.36 | 0.25 | 0.01 | 0.26 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.36 | 0.25 | 0.01 | 0.26 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.76 | 1.35 | 1.66 | 1.93 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.40 | -1.10 | -1.65 | -1.67 |
Non-Operating Income | NA | 1.62 | 0.73 | 0.79 | 0.02 |
Interest Expense | NA | 0.32 | 0.32 | 0.28 | 0.34 |
Pretax Income | NA | -0.11 | -0.70 | -1.14 | -1.98 |
Income Taxes | NA | 0.00 | 0.03 | 0.01 | 0.01 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -0.11 | -0.73 | -1.15 | -1.99 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -0.11 | -0.73 | -1.15 | -1.99 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 121.27 | 121.27 | 121.27 | 120.33 |
Diluted EPS Before Non-Recurring Items | NA | 0.00 | -0.01 | -0.01 | -0.02 |
Diluted Net EPS (GAAP) | NA | 0.00 | -0.01 | -0.01 | -0.01 |